IXICO announces enhanced contracts with two pharmaceutical company customers in Huntington’s disease

IXICO today announces that the contracts for two separate clinical trials in Huntington’s disease (‘HD’) with two top 15 pharmaceutical companies (previously announced in May 2014) have been extended. As a consequence, IXICO anticipates the revenue from these two contracts to be significantly enhanced to a potential £2.5 million over approximately three years. Building on the continued contract wins and a healthy pipeline referenced in the trading update released in July 2014, the significant value of these contracts gives the board increasing confidence in the prospects for IXICO’s clinical trials business.

By |2017-10-11T12:15:15+00:0026 November 2014|Contracts|